Several miRNAs have been reported to target members of the RAS/ERK pathway [18], and dysregulation of those miRNAs in cancer cells likely contributes to tumorigenesis by aberrantly activating the RAS/ERK pathway. The gene discussed is MAPK1; the disease is cancer.